Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week randomized double-blind trial of ofatumumab in relapsing multiple sclerosis with open-label extension
jRCT2080223655Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing Ofatumumab arm with Placebo arm (2 arms). Started Sep 2017; status: completed.
02
Drugs
ofatumumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on jRCT2080223655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223655.